HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage I Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7
Conditions
Brief summary
This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive breast cancer (confined to the breast or the breast and lymph nodes under the arm). Drugs used in chemotherapy, such as cyclophosphamide and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving cyclophosphamide, paclitaxel, and trastuzumab after surgery may help prevent the cancer from coming back.
Detailed description
PRIMARY OBJECTIVES: I. To determine the toxicities and ability to complete the planned treatment of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2/neu positive breast cancer. II. To estimate recurrence free survival of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2/neu positive breast cancer. OUTLINE: SYSTEMIC THERAPY: Patients receive cyclophosphamide intravenously (IV) over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard National Comprehensive Care Network (NCCN) guidelines. After completion of study treatment, patients are followed up every 3 months for 2 years.
Interventions
DRUGCyclophosphamide
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGPaclitaxel
Given IV
BIOLOGICALTrastuzumab
Given IV
Sponsors
University of Nebraska
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed newly diagnosed stage I-II HER2/neu positive breast cancer * Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment * Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Within 30 days prior to enrollment: Absolute neutrophil count greater than or equal to 1,500/mcl * Within 30 days prior to enrollment: Platelet count equal to or greater than 150,000/mcl * Within 30 days prior to enrollment: Hemoglobin \> 11 gm/dl * Within 30 days prior to enrollment: Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN) * Within 30 days prior to enrollment: Total bilirubin equal to or less than 1.5 times the ULN * Within 30 days prior to enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN * Within 30 days prior to enrollment: Creatinine less than 1.5 times the ULN * Able to give informed consent * All included subjects must have normal cardiac function as defined by an ejection fraction of \> 50% by echocardiogram * Able to return for treatment and follow-up on the specified days
Exclusion criteria
* Prior malignancy; except for adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas * Subjects with pre-existing grade II peripheral neuropathy * History of previous chemotherapy * Stage IV or metastatic breast cancer * Pregnant or nursing women * Inability to cooperate with treatment protocol * No active serious infections or other conditions precluding chemotherapy * Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol e.g. unstable angina, myocardial infarction within 6 months, severe infection, etc. * Known hypersensitivity to any component of required drugs in the study * Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiographic (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Neutropenia | From initiation of study treatment through completion of therapy and up to 3 months after the final dose of study treatment (including trastuzumab). | Number of participants who experienced treatment-emergent neutropenia graded according to National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) v4.03. |
| Number of Participants With Paclitaxel-related Neuropathy | From initiation of study treatment through completion of therapy and up to 3 months after the final dose of study treatment (including trastuzumab). | Number of Participants who experienced paclitaxel-related neuropathy graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. |
| Number of Participants With Cardiotoxicity Grade 3/4 Cardiotoxicity, Graded According to the NCI CTCAE v4.03 | From initiation of study treatment through completion of therapy and up to 3 months after the final dose of study treatment (including trastuzumab). | Number of Participants who experienced grade 3/4 cardiotoxicity with standard treatment, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. |
| Number of Participants With Grade 3/4 Nausea/Vomiting, Graded According to the NCI CTCAE v4.03 | From initiation of study treatment through completion of therapy and up to 3 months after the final dose of study treatment (including trastuzumab). | Participants that experienced grade 3/4 nausea/vomiting with this regimen when compared to standard regimens. |
| Number of Participants With Recurrence Free Survival (RFS) | First date of therapy until the first notation of clinical progression, relapse or death from any cause, assessed at 2 years | RFS and survival curves will be plotted following the method of Kaplan and Meier using the full analysis set. |
| Number of Participants With Inability to Complete Treatment, Defined as a Patient That Requires a Lower Dose of Therapy (Defined as Dose Lowered by 50%), or a Postponement of Scheduled Treatment of Longer Than 28 Days, or Discontinuation for Any Reason | Up to 2 years | Number of participants with inability to complete treatment, defined as a patient that requires a lower dose of therapy (defined as dose lowered by 50%), or a postponement of scheduled treatment of longer than 28 days, or discontinuation of treatment for any reason. will be described using frequencies and proportions and 90% confidence intervals. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAmulya Yellala, MD
University of Nebraska
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 56.10 years STANDARD_DEVIATION 11.06 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 20 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 20 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 19 |
| other Total, other adverse events | 17 / 19 |
| serious Total, serious adverse events | 6 / 19 |
Outcome results
None listed